Brukinsa zanubrutinib

Dec 2021: BRUKINSA (Zanubrutrinib) is a prescription drug from BeiGene ltd. BRUKINSA is used to treat adults with Mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM) & marginal zone lymphoma (MZL)  who have had at least one prior cancer treatment. Waldenström’s macroglobulinemia is a type of macroglobulinemia caused by Waldenström’s (WM). Patients can buy Brukinsa online.

When taken at the authorized total daily dose of 320 mg, BRUKINSA® (zanubrutinib) has been found to block 100 percent of BTK in blood cells and 94 percent to 100 percent of BTK in lymph nodes. The impact of totally inhibiting BTK on treatment outcomes has yet to be determined.

BRUKINSA is a treatment for people who have had at least one prior treatment for mantle cell lymphoma (MCL).

The approval of BRUKINSA was based on the response rate. This use is still being evaluated to see if it has any clinical benefit. BRUKINSA is not known to be safe or effective in children.

The protein Bruton’s tyrosine kinase (BTK) has been related to MCL.

Why is a BTK inhibitor helpful in the treatment of mantle cell lymphoma (MCL)?

MCL is caused by malignant B cells that proliferate and disseminate quickly.
BTK (Bruton’s tyrosine kinase) is a protein that helps malignant B cells grow and spread by sending signals to them.
BTK blockade can help to inhibit this signaling.
The impact of totally inhibiting BTK on treatment outcomes has yet to be determined.

How well Brukinsa works?

In 2 clinical studies, 118 patients with MCL received BRUKINSA after at least 1 prior therapy. In both clinical studies, 84% patients responded to treatment, known as the overall response rate and nearly 80% continued to respond for a year or longer. 

What are the possible side effects of Brukinsa?

BRUKINSA may cause serious side effects, including:

Hemorrhage is a dangerous bleeding problem that can lead to death. If you are also taking a blood thinner, your risk of bleeding may increase. If you have any signs or symptoms of bleeding, tell your doctor, including:

• blood in your stools or black stools (looks like tar)
• pink or brown urine
• unexpected bleeding, or bleeding that is severe or you cannot control
• vomit blood or vomit that looks like coffee grounds
• cough up blood or blood clots
• increased bruising
• dizziness
• weakness
• confusion
• changes in your speech
• headache that lasts a long time.

Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.

• Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with BRUKINSA, but can also be severe. Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.
• Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin. Use sun protection when you are outside in sunlight.
• Heart rhythm problems (atrial fibrillation and atrial flutter). Tell your healthcare provider if you have any of the following signs or symptoms:
  
  • your heartbeat is fast or irregular
  • feel lightheaded or dizzy
  • pass out (faint)
  • shortness of breath
  • chest discomfort

How Brukinsa is taken?

The recommended dose of BRUKINSA is 320 mg daily, which is four 80-mg capsules. Your doctor may recommend taking BRUKINSA: twice daily or once daily.

BRUKINSA capsules should be taken whole with water—do not open, break, or chew. BRUKINSA can be taken with or without food.

Your dose and schedule may be changed or interrupted by your doctor to meet your individual treatment needs including managing side effects.

Approvals 

Approval’s as on Dec 2021.

BRUKINSA is approved in the following indications and regions:

• For the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy (United States, November 2019)^a;
• For the treatment of MCL in adult patients who have received at least one prior therapy (China, June 2020) ^b;
• For the treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have received at least one prior therapy (China, June 2020) ^b;
• For the treatment of relapsed or refractory MCL (United Arab Emirates, February 2021);
• For the treatment of Waldenström’s macroglobulinemia (WM) in adult patients (Canada, March 2021);
• For the treatment of adult patients with WM who have received at least one prior therapy (China, June 2021)^b;
• For the treatment of MCL in adult patients who have received at least one prior therapy (Canada, July 2021);
• For the treatment of MCL in adult patients who have received at least one prior therapy (Chile, July 2021);
• For the treatment of adult patients with MCL who have received at least one previous therapy (Brazil, August 2021);
• For the treatment of adult patients with WM (United States, August 2021);
• For the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen (United States, September 2021)*;
• For the treatment of adult patients with MCL who have received at least one previous therapy (Singapore, October 2021);
• For the treatment of MCL in patients who have received at least one prior therapy (Israel, October 2021);
• For the treatment of adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy (Australia, October 2021);
• For the treatment of adult patients with MCL who have received at least one prior therapy (Australia, October 2021);
• For the treatment of adult patients with MCL who have received at least one previous therapy (Russia, October 2021);
• For the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy (Saudi Arabia, November 2021); and
• For the treatment of adult patients with WM who have received at least one prior therapy or first-line treatment of patients unsuitable for chemo-immunotherapy (European Union, November 2021).

Brukinsa price in India

The cost for Brukinsa oral capsule 80 mg is between $ 3500-4000 for a supply of 120 capsules, depending on the pharmacy you visit.

Can I buy Brukinsa online?

Yes, you can buy Brukinsa online. Many online pharmacies are selling it online but with only valid prescriptions.

For more information please call, message or WhatsApp +91 961588 1588.

Please click here for prescribing information of Brukinsa.